Resolvin D1 in Psoriasis Before and After Narrowband UVB Phototherapy

Not Applicable

• Conditions: Psoriasis

• Registration Number: NCT03483311
• Lead Sponsor: Cairo University

Brief Summary

• Assessment of tissue level of resolvin D1 in psoriasis in comparison to its level in healthy controls in order to verify its role in the pathogenesis of psoriasis.

Detailed Description

Not available

Study Timeline

• Status Verified: 2018-03
• Study Start: 2018-03-01
• Study First Submitted: 2018-03-23
• Study First Submitted QC: 2018-03-23
• Last Update Submitted: 2018-03-23
• Study First Posted: 2018-03-30
• Last Update Posted: 2018-03-30
• Primary Completion: 2018-09
• Study Completion: 2018-09

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• Patients with psoriasis (adults and children above 12years)
• Both sexes.
• New cases or cases not receiving any treatment for at least 3 months ago.

Exclusion Criteria

• Any contraindication to phototherapy treatment (e.g. Photosensitizing creams or medications, past skin cancer, especially melanoma, etc...)
• Erythrodermic and pustular psoriasis.
• History of autoimmune diseases or other systemic diseases (e.g. Alzheimer's disease, fibromyalgia, cystic fibrosis)

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Tissue levels of resolvin D1 in psoriatic patients before and after NB-UVB.	6 months

Trial Locations

Locations (1)

Maha Fathy Elmasry; 🇪🇬 Cairo, Egypt